Evolution of the Average Target: Cognition Therapeutics, Inc.

Evolution of the Average Target - Cognition Therapeutics, Inc.

Evolution of the Target Price: Cognition Therapeutics, Inc.

Evolution of the Target Price - Cognition Therapeutics, Inc.

Changes in Analyst Recommendations: Cognition Therapeutics, Inc.

d62ed2f1e9303c0.bpVSqbDJiUVvBhfj40OgKxT238_689M0u_nvmQRUNFU.L88g5daZ4gglc1GVsQj0ZWSp7YqJp-d5g7rC6kwlQB8p-2XC56LnNwViZA~b317ced1d53a05daab90bcfa84ec122a
11-21 B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating MT
25-08-07 Cognition Therapeutics Q2 net loss narrows to $6.7 mln RE
25-02-06 B. Riley Adjusts Cognition Therapeutics Price Target to $2 From $1.50, Maintains Buy Rating MT
24-12-19 B. Riley Upgrades Cognition Therapeutics to Buy From Neutral, Lifts PT to $1.50 From $1 MT
24-08-06 B. Riley Downgrades Cognition Therapeutics to Neutral From Buy, $1 Price Target MT
24-07-30 Cantor Fitzgerald Downgrades Cognition Therapeutics to Neutral From Overweight MT
24-06-07 Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target MT
24-05-29 HC Wainwright Starts Cognition Therapeutics With Buy Rating, $10 Price Target MT
23-08-14 Ladenburg Thalmann Cuts Cognition Therapeutics' Price Target to $6 From $10, Keeps Buy Rating MT
23-04-06 B. Riley Cuts Cognition Therapeutics' PT to $5 From $15, Notes Near-Term Dilution, Expanding R&D Efforts to Execute on Phase II/III Programs; Keeps Buy Rating MT
22-11-15 Oppenheimer Adjusts Cognition Therapeutics Price Target to $9 From $18, Maintains Outperform Rating MT
22-09-29 Cantor Fitzgerald Starts Cognition Therapeutics at Overweight With $12 Price Target MT
22-04-22 Ladenburg Thalmann Starts Cognition Therapeutics at Buy With $10 Price Target MT
22-04-01 B. Riley Lowers Cognition Therapeutics' PT to $15 from $20, Keeps Buy Rating MT
22-03-31 Oppenheimer Adjusts Cognition Therapeutics' Price Target to $18 From $22, Maintains Outperform Rating MT
22-01-24 B. Riley Lowers Cognition Therapeutics' Price Target to $20 from $27 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
21-11-03 Oppenheimer Starts Cognition Therapeutics at Outperform with $22 PT On Potential Offered By Lead Dementia Drug Candidate CT1812 MT
21-11-03 B. Riley Starts Cognition Therapeutics at Buy with $27 PT, Notes Conviction in Proprietary, Mid-Stage Pipeline MT
21-11-03 Oppenheimer Starts Cognition Therapeutics at Outperform with $22 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+375.78%
+35.78%
+28.93%
+10.89%
+8.75%
+14.18%
+37.21%
+37.85%
+32.7%
+4.59%
Average +58.67%
Weighted average by Cap. +23.89%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.7006USD
Average target price
3.333USD
Spread / Average Target
+375.78%
High Price Target
4.000USD
Spread / Highest target
+470.94%
Low Price Target
3.000USD
Spread / Lowest Target
+328.20%

Analyst Consensus Detail

Analyst consensus - Cognition Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Cognition Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cognition Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CGTX Stock
  4. Consensus Cognition Therapeutics, Inc.